In this meta-analysis, we summarized the effects of DPP4 inhibitors on glucagon levels in patients with T2DM.<h4>Materials and methods</h4>Randomized controlled trials (RCTs) comparing the influence of DPP4 inhibitors on circulating glucagon levels with placebo or other oral antidiabetic drugs (OADs) in patients with T2DM were identified by searches of Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library). Here, DPP4 is linked to type 2 diabetes mellitus.